Evidence map›Paper›PMID 36193709›Full record

ArticleClinical cardiology2022

Impact of frailty on mortality and quality of life in patients with a history of cancer undergoing transcatheter aortic valve replacement.

Nikitha Kosaraju, Perry Wu, Mei Leng, Marielle Bolano, Asim M Rafique, John Shen, Nancy Satou, Jeanne Huchting, Deena Goldwater, Olcay Aksoy and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Nikitha KosarajuDavid Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
Perry WuDepartment of Medicine, Division of Cardiology, University of California at Irvine, Orange, California, USA.
Mei LengDepartment of Medicine, Division of General Internal Medicine and Health Services Research, University of California at Los Angeles, Los Angeles, California, USA.
Marielle BolanoDepartment of Medicine, Division of Geriatrics, University of California at Los Angeles, Los Angeles, California, USA.
Asim M RafiqueDepartment of Medicine, Division of Cardiology, University of California at Los Angeles, Los Angeles, California, USA.
John ShenDepartment of Medicine, Division of Hematology/Oncology, University of California at Los Angeles, Los Angeles, California, USA.
Nancy SatouDepartment of Surgery, Division of Cardiac Surgery, University of California at Los Angeles, Los Angeles, California, USA.
Jeanne HuchtingDepartment of Medicine, Division of Cardiology, University of California at Los Angeles, Los Angeles, California, USA.
Deena GoldwaterWelcome Health Medical Group, Welcome Health Inc, Long Beach, California, USA.
Olcay AksoyDepartment of Medicine, Division of Cardiology, University of California at Los Angeles, Los Angeles, California, USA.
Eric H YangDepartment of Medicine, Division of Cardiology, University of California at Los Angeles, Los Angeles, California, USA.ORCID http://orcid.org/0000-0003-4889-7454
University of California, Los Angeles · USLos Angeles County Department of Health Services · USMedical Healthcom (Czechia) · CZUniversity of California, Irvine · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Department of Medicine, UCLANCATS NIH HHS UL1 TR001881UCLA Clinical and Translational Science Institute UL1TR001881
6 · The paper itself

Abstract

backgroundTranscatheter aortic valve replacement (TAVR) is increasingly offered for aortic stenosis (AS) treatment in patients with a history of cancer. The impact of frailty on outcomes in this specific patient population is not well described. HYPOTHESIS: Frailty is associated with mortality and poorer quality of life (QOL) outcomes in patients undergoing TAVR with a history of cancer.

methodsThis retrospective single center cohort study included AS patients who underwent TAVR from August 1, 2012 to May 15, 2020. Frailty was measured using serum albumin, hemoglobin, gait speed, functional dependence, and cognitive impairment. The primary outcome was a composite of all-cause mortality and QOL at 1 year. A poor primary outcome was defined as either all-cause mortality, Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) score <45 or a KCCQ-OS score decline of ≥10 points from baseline. Regression analysis was used to determine the impact of frailty on the primary outcome.

resultsThe study population was stratified into active/recent cancer (n = 107), remote cancer (n = 85), and non-cancer (n = 448). Univariate analysis of each cohort showed that frailty was associated with the primary outcome only in the non-cancer cohort (p = .004). Multivariate analysis showed that cancer history was not associated with a poor primary outcome, whereas frailty was (1.7 odds ratio, 95% confidence interval [CI]: 1.1-2.8; p = .028).

conclusionsFrailty is associated with mortality and poor QOL in the overall and non-cancer cohorts. Further investigation is warranted to understand frailty's effect on the cancer population. Frailty should be heavily considered during TAVR evaluation.

Indexed as

Aortic Valve StenosisFrailtyNeoplasmsTranscatheter Aortic Valve ReplacementAortic ValveCohort StudiesHumansQuality of LifeRetrospective StudiesRisk FactorsSerum AlbuminTreatment OutcomeSerum Albumincardio-oncologyKCCQreadmissionstructural heart diseasetranscatheter aortic valve replacement

Identifiers

PMID36193709
PMCPMC9574730
OpenAlexW4301390834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.